#1 Clinical Trials Search in Europe

Pazopanib

Pazopanib is an oral medication being studied in various clinical trials for its potential in treating different types of cancer. This article examines the use of pazopanib in clinical trials, focusing on its effectiveness, safety profile, and applications in conditions such as soft tissue sarcomas, renal cell carcinoma, and ovarian cancer. The trials aim to evaluate pazopanib’s ability to inhibit tumor growth and improve patient outcomes.

Table of Contents

What is Pazopanib?

Pazopanib is a medication used in the treatment of various types of cancer. It is also known by other names such as GW786034 and Votrient[3][2]. Pazopanib belongs to a class of drugs called tyrosine kinase inhibitors, which work by targeting specific proteins involved in cancer growth[1].

How Pazopanib Works

Pazopanib works by inhibiting multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptors (PDGFA and B), and c-Kit. These receptors are involved in the process of angiogenesis (the formation of new blood vessels) and cancer progression[2]. By blocking these receptors, pazopanib helps to:

  • Reduce the blood supply to tumors, limiting their source of oxygen and nutrients
  • Slow down or stop the growth of cancer cells
  • Prevent the spread of cancer to other parts of the body

Conditions Treated with Pazopanib

Pazopanib has been studied and used in the treatment of various types of cancer, including:

  • Soft Tissue Sarcoma: A type of cancer that develops in soft tissues such as muscles, tendons, and fat[1]
  • Renal Cell Carcinoma: A type of kidney cancer[3]
  • Advanced Angiosarcoma: A rare cancer that develops in the inner lining of blood vessels and lymph vessels[2]
  • Non-Small Cell Lung Cancer: A type of lung cancer that is less aggressive than small cell lung cancer[4]
  • Urothelial Carcinoma: A type of bladder cancer[5]

How Pazopanib is Administered

Pazopanib is typically administered in the following ways:

  • Oral tablets: The most common form of pazopanib is taken by mouth, usually at a dose of 800 mg once daily[1]
  • Eye drops: In some studies, pazopanib has been formulated as eye drops for conditions like macular degeneration[6]
  • Intravenous (IV) injection: In certain research settings, pazopanib has been administered through an IV for pharmacokinetic studies[3]

The specific dosage and administration method may vary depending on the condition being treated and individual patient factors. It’s important to take pazopanib exactly as prescribed by your healthcare provider.

Pazopanib in Clinical Trials

Pazopanib has been extensively studied in various clinical trials to evaluate its effectiveness and safety. Some notable trials include:

  • A study comparing pazopanib to placebo in patients with soft tissue sarcoma[1]
  • A trial evaluating pazopanib in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma[7]
  • Research on pazopanib as an adjuvant therapy (additional treatment after surgery) for stage I non-small cell lung cancer[4]
  • A study comparing pazopanib plus TRC105 (another cancer drug) to pazopanib alone in patients with advanced angiosarcoma[2]

These clinical trials help researchers understand how well pazopanib works for different types of cancer and in combination with other treatments.

Potential Side Effects

Like all medications, pazopanib can cause side effects. Some potential side effects observed in clinical trials include:

  • Changes in blood pressure (both high and low)[1]
  • Alterations in heart rate[1]
  • Changes in blood cell counts (e.g., hemoglobin, white blood cells, platelets)[1]
  • Liver function changes[1]
  • Fatigue
  • Nausea or vomiting
  • Diarrhea

It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking pazopanib.

Aspect Details
Drug Name Pazopanib (also known as GW786034, Votrient)
Mechanism of Action Inhibits multiple receptor tyrosine kinases, including VEGFR-1, VEGFR-2, and VEGFR-3
Cancer Types Studied Advanced angiosarcoma, renal cell carcinoma, soft tissue sarcomas, ovarian cancer, neuroblastoma
Administration Oral tablets or powder suspension, typically 400-800 mg daily
Primary Outcomes Measured Progression-free survival, objective response rate, metabolic response rate
Secondary Outcomes Overall survival, safety profile, pharmacokinetics, biomarker changes
Imaging Techniques Used PET-CT, MRI, RECIST criteria
Common Side Effects Changes in blood pressure, heart rate, liver function tests, blood cell counts
Unique Applications Preoperative therapy in high-risk soft tissue sarcoma, combination with other drugs
Patient Populations Adults with various solid tumors, including pediatric patients in some trials

FAQ

  • What is pazopanib and how does it work? Pazopanib is an oral medication that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs). It works by blocking the growth of new blood vessels that supply tumors, potentially slowing or stopping cancer growth.
  • What types of cancer is pazopanib being studied for? Clinical trials are investigating pazopanib for various cancers, including advanced angiosarcoma, renal cell carcinoma, soft tissue sarcomas, ovarian cancer, and neuroblastoma.
  • How is pazopanib administered in clinical trials? In most trials, pazopanib is given orally, either as tablets or as a powder suspension. The typical daily dose ranges from 400 mg to 800 mg, depending on the specific trial and patient characteristics.
  • What are some common side effects of pazopanib observed in clinical trials? Common side effects may include changes in blood pressure, heart rate, liver function tests, and blood cell counts. Researchers closely monitor patients for these and other potential adverse events during the trials.
  • How do researchers measure the effectiveness of pazopanib in clinical trials? Effectiveness is measured through various methods, including tumor response rates, progression-free survival, overall survival, and changes in specific biomarkers like CA-125 for ovarian cancer. Imaging techniques such as PET-CT and MRI are also used to assess tumor response.

Ongoing Clinical Trials on Pazopanib

  • Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study of Spartalizumab and Pazopanib for Patients with Refractory or Recurrent Solid Tumors

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Pembrolizumab and Epacadostat vs Standard Treatment for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effectiveness of Nivolumab, Ipilimumab, and Pazopanib in Patients with Advanced Rare Sarcomas

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Tyrosine Kinase Inhibitor (TKI): A type of drug that blocks specific enzymes called tyrosine kinases, which are involved in cell signaling and growth. Pazopanib is an example of a TKI.
  • Vascular Endothelial Growth Factor Receptor (VEGFR): A protein on the surface of cells that binds to vascular endothelial growth factor (VEGF), which stimulates the formation of new blood vessels. Pazopanib targets these receptors.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening. This is a common measure of effectiveness in cancer clinical trials.
  • RECIST Criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment based on changes in tumor size.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This is important for understanding how pazopanib behaves in patients.
  • Biomarker: A measurable substance in the body that can indicate the presence of disease, infection, or environmental exposure. In cancer trials, biomarkers can help assess treatment effectiveness.
  • CA-125: Cancer Antigen 125, a protein found in higher amounts in tumor cells, particularly ovarian cancer. It's used as a biomarker in some pazopanib trials.
  • Angiogenesis: The process of forming new blood vessels. Pazopanib works by inhibiting angiogenesis, which can slow or stop tumor growth.
  • Metabolic Response: A change in the metabolic activity of cancer cells, often measured by PET scans, which can indicate how well a treatment like pazopanib is working.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment. Monitoring adverse events is crucial in clinical trials to assess drug safety.

References

  1. https://clinicaltrials.gov/study/NCT00753688
  2. https://clinicaltrials.gov/study/NCT02979899
  3. https://clinicaltrials.gov/study/NCT00478725
  4. https://clinicaltrials.gov/study/NCT00775307
  5. https://clinicaltrials.gov/study/NCT01622660
  6. https://clinicaltrials.gov/study/NCT01072214
  7. https://clinicaltrials.gov/study/NCT01418001